GGrantIndex
← Search

CORE--BIOCHEMISTRY AND BIOTECHNOLOGY

$196,218P30FY2002CANIH

Fox Chase Cancer Center, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567Paper 39602533Paper 39554190Paper 39546469Paper 39521739Paper 39514554Paper 39371220Paper 39345610Paper 39343653Paper 39223207Paper 39207123Paper 39189642Paper 39148468Paper 39137728Paper 39072643Paper 39060143Paper 39013784Paper 39003201Paper 38982062Paper 38976159Paper 38963567Paper 38914477Paper 38871720Paper 38865671Paper 38853421Paper 38835516Paper 38815457Paper 38811332Paper 38798370Paper 38766032Paper 38747616Paper 38678525Paper 38659828Paper 38639476Paper 38638131Paper 38600381Paper 38586274Paper 38586042Paper 38559274Paper 38547779Paper 38539515Paper 38464238Paper 38452871Paper 38432028Paper 38421650Paper 38377387Trial NCT04290585Trial NCT03177057Trial NCT02594826Trial NCT02132884Trial NCT02132858Trial NCT02132845Trial NCT02110953Trial NCT02092714Trial NCT02050009Trial NCT01982591Trial NCT01962948Trial NCT01934179Trial NCT01840150Trial NCT01462630Trial NCT01316757Trial NCT01212822Trial NCT00750009Trial NCT00509626Trial NCT00458588Trial NCT00436397Trial NCT00433524Trial NCT00084591Trial NCT00084539Trial NCT00084526Trial NCT00084513Trial NCT00066677Trial NCT00062322Trial NCT00062309Trial NCT00043108Trial NCT00039520Trial NCT00039507Trial NCT00022308Trial NCT00021398Trial NCT00021372Trial NCT00021346Trial NCT00021333Trial NCT00021320Trial NCT00005037Trial NCT00003264Trial NCT00003263Trial NCT00003109Patent 9533040Patent 9182383Patent 9101603Patent 8980258Patent 8685658Patent 8609437Patent 8580263Patent 8329873Patent 7332585Patent 7332580Patent 7129057Patent 6946275Patent 6617427

Abstract

Description: (Applicant's Description) The Biochemistry and Biotechnology Facility (BBF) makes available to Fox Chase investigators three state-of-the-art services that are connected to each other in research applications. DNA Technology provides uniformly high quality DNA, RNA, and modified oligonucleotides, the assembly of designer genes, and mutation detection by our patented process. Because of quality control, oligonucleotides from BBF have never been a variable in the users' experiments. DNA Technology leads to new genes and proteins that are further supported by the Biotechnology services of BBF. These include protein expression, fermentation, purification of enzymes and peptides, phage-displayed antibodies, and HPLC applications. A new addition is the BIAcore biosensor with which protein-ligand interactions are now investigated effectively. Through BBF, translational research projects gain instant access to equipment, manpower, and expertise in cutting edge technologies, and new investigators can quickly get up to speed. With institutional and CCSG developmental funds, the BBF has extended the above research with modern Mass Spectrometry. Services include high sensitivity protein analysis and identification, partial peptide sequencing, characterization of post-translational modifications, DNA analysis, drug chemistry, and enzyme characterization. In the cell, post-translational modifications of the proteins and changes in the level of key proteins provide important mechanisms whereby cellular processes are controlled. This important area of cancer biology is currently best addressed by combining 2D gel electrophoresis with mass spectrometry. BBF is using these techniques to assist many research programs at FCCC, and proposes to achieve even higher efficacy in the next CCSG cycle. BBF services support 52 peer-review funded principal investigators in all 13 Programs in all three Divisions. The staff of BBF is thoroughly cross-trained to assist each other. Because of the readiness of instruments, manpower, and experience, the efficacy of the BBF is impossible in the settings of individual laboratories. The BBF staff make frequent contact with the Facility users to determine how the Facility can best serve them. This energetic style of operation stimulates scientific interactions and the dissemination of ideas. Many projects have facilitated the obtaining of new peer-review support, new collaborations, publications, and patents.

View original record on NIH RePORTER →